Skip to main content
SpringerLink
Log in

Bevacizumab priced high, sales expected to exceed $US2b in 2009

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bevacizumab priced high, sales expected to exceed $US2b in 2009. Pharmacoecon. Outcomes News 448, 11 (2004). https://doi.org/10.2165/00151234-200404480-00024

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200404480-00024

Keywords

Search

Navigation